Celestra logo

Celestra Health Systems Gains Market Traction

CELESTRA HEALTH SYSTEMS — Leader in AI-based monitoring of multiple sclerosis

This past quarter, the team at Celestra Health took their Multiple Sclerosis Treatment Management Solution on the road, receiving invaluable feedback and market traction.

In October, key personnel from Celestra Health travelled to London to meet with the UK National Health Service (NHS) and UK-based Multiple Sclerosis (MS) patient organizations, as well as conducting a Site Initiation Visit (SIV) at the Royal London Hospital (part of Barts Health NHS Trust), who are now recruiting patients for our Phase II clinical study being conducted in the US, the UK and Canada. We then headed to Milan to attend ECTRIMS 2023, the world’s largest MS Neurology conference, to participate in meetings with targeted customers and investors; the four abstracts prepared by our research team were officially published by ECTRIMS at the conference. We successfully demonstrated our production-grade platform to key stakeholders, including global pharmaceutical companies, research organizations and patient groups. Our AI-based platform generated a significant amount of excitement, as evidenced in our CEO’s lively interview with a prominent MS YouTuber: bit.ly/3sgx3Hg.

In November, in addition to participating in the SaaS North conference in Ottawa, we plan to complete our Parkinson’s Disease Phase I clinical study that is now underway. We are also collaborating with the largest MS clinic in Germany, with plans to adapt our remote patient monitoring solution for use in MS clinics in Germany and beyond; this initiative will broaden the applicability of our solution and allow us to take advantage of existing reimbursement codes for in-clinic gait assessments. And perhaps most importantly, we are submitting our application to the FDA for Breakthrough Device Designation, along with our FDA Pre-Submission application. All in all, a very busy and successful two months for the Celestra Health team!